Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.
Saved in:
| Title: | Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy. |
|---|---|
| Authors: | Shin SS; Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, California., Modongo C; Botswana-UPenn Partnership, Gaborone, Botswana.; Department of Infectious Disease, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA., Zetola NM; Botswana-UPenn Partnership, Gaborone, Botswana. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2020 Jun 24; Vol. 71 (1), pp. 242-243. |
| Publication Type: | Letter; Research Support, N.I.H., Extramural; Comment |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciz917 |
